We are monitoring the impact of COVID-19 & Recession alarm on North America Ovarian Cancer Market Get in touch with us for detailed analysis Know More
Share on

North America Ovarian Cancer Market Research Report – Segmented By Stage Of Cancer, Cancer Type, Diagnosis, Type Of Treatment & Country (the United States, Canada and Rest of North America) – Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast (2022 to 2027)

Published: January, 2022
ID: 1392
Pages: 181

North American Ovarian Cancer Market Size (2022 to 2027)

The North American Ovarian Cancer Market size is forecasted to grow at a promising rate between 2022 to 2027.

Due to the rising incidence of ovarian cancer in the region, the North American region is expected to play a leading role in the global market during the forecast period. The patent expiration of certain top pharmaceuticals may also help to propel the industry by encouraging new companies to enter the market. These altering dynamics are projected to drive the ovarian cancer market during the forecast period. As a result, the North American market for ovarian cancer drugs is expected to grow rapidly. In addition, the ovarian cancer medications market is boosted by ongoing research and development to offer effective treatment interventions for various disorders.

Several ovarian cancer treatments are now in clinical trials and are likely to hit the market in the near future. In addition, ovarian cancer has become more common in recent years as the female population has aged. Some of the important reasons driving the growth of the ovarian cancer market are rising ovarian cancer prevalence, the launch of new medications and therapies, increased healthcare expenditure, and increased government funding. Furthermore, growing healthcare awareness is propelling the North American ovarian cancer market forward.

The North American ovarian cancer diagnostics and therapies market is further growing due to the growing elderly population. It's crucial to get an accurate diagnosis for ovarian cancer since, in most cases, the disease has already advanced to the lymph nodes and outside of the pelvis by the time it's discovered. Drugs like Bevacizumab (Avastin) and Pazopanib (Votrient) are expected to enhance the market, now dominated by generics like paclitaxel and carboplatin. In addition, the market is expected to benefit significantly from the development of new medications to treat this form of cancer. During the forecast period, these changing dynamics are expected to drive the ovarian cancer market.

However, the lack of accurate early-stage diagnostic procedures for ovarian cancer can also negatively affect the ovarian cancer market. In the development of increasingly effective drugs, the North American ovarian cancer market may confront a problem.

This research report on the North American ovarian cancer market has been segmented and sub-segmented into the following categories:

By Stage of Cancer:

  • Stage I
    • Stage IA
    • Stage IB
    • Stage IC
  • Stage II
    • Stage IIA
    • Stage IIB
    • Stage IIC
  • Stage III
    • Stage IIIA
    • Stage IIIB
    • Stage IIIC
  • Stage IV

By Cancer Type:

  • Primary Peritoneal Carcinoma
  • Ovarian Stromal Tumors
  • Ovarian Germ Cell Tumors
  • Epithelial Ovarian Tumors

By Diagnosis:

  • Physical Examination
  • Blood Tests
  • Ultrasound
  • PET
  • CT Scan
  • MRI
  • Human Chorionic Gonadotropin Test
  • Biopsy

By Type of Treatment:

  • Chemotherapy
  • Radiation Therapy
  • Hormonal Therapy
  • Surgery
  • Immunotherapy
  • Targeted Therapy

By Country:

  • The United States
  • Canada
  • Rest of North America

The market for ovarian cancer diagnostics and therapeutics in North America is expected to dominate the United States during the forecast period. In the United States, ovarian cancer is the ninth most frequent cancer in women, hence the fifth leading cause of cancer mortality. The bulk of ovarian cancer diagnostics companies are situated in the United States, a significant competitive advantage for the region. Women between the ages of 55 and 64 are more likely to get ovarian cancer. Bloating, pelvic and abdominal pain, difficulty eating, and urine symptoms are common in ovarian cancer. The expansion of the North American ovarian cancer diagnostics and therapeutics market is being fuelled by the rising prevalence of ovarian cancer worldwide and the increased usage of combination medicines to treat ovarian cancer.

KEY MARKET PLAYERS:

A few of the notable participants in the North American ovarian cancer market profiled in this report are Aetera Zenteris Inc., Eli Lilly and Company, Roche, Amgen, Janssen Pharmaceuticals, Inc., Bristol Myers Squibb Company, Novogen, Inc., GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca, and Genentech Inc.

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                           

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                              

                2.2 Research Phases                      

                                2.2.1 Secondary Research            

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling     

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                      

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                             

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                      

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

5. Market Segmentation                                              

                5.1 Stage Of Cancer                        

                                5.1.1 Stage I       

                                                5.1.1.1 Stage IA

                                                5.1.1.2 Stage IB

                                                5.1.1.3 Stage IC

                                5.1.2 Stage II     

                                                5.1.2.1 Stage IIA

                                                5.1.2.2 Stage IIB

                                                5.1.2.3 Stage IIC

                                5.1.3 Stage III    

                                                5.1.3.1 Stage IIIA

                                                5.1.3.2 Stage IIIB

                                                5.1.3.3 Stage IIIC

                                5.1.4 Stage IV    

                                5.1.5 Y-o-Y Growth Analysis, By Stage Of Cancer

                                5.1.6 Market Attractiveness Analysis, By Stage Of Cancer               

                                5.1.7 Market Share Analysis, By Stage Of Cancer

                5.2 Type                              

                                5.2.1 Introduction           

                                5.2.2 Primary Peritoneal Carcinoma        

                                5.2.3 Ovarian Stromal Tumors   

                                5.2.4 Ovarian Germ Cell Tumors

                                5.2.5 Epithelial Ovarian Tumors

                                5.2.6 Y-o-Y Growth Analysis, By Type      

                                5.2.7 Market Attractiveness Analysis, By Type     

                                5.2.8 Market Share Analysis, By Type      

                5.3 Diagnosis                     

                                5.3.1 Introduction           

                                5.3.2 Physical Examination          

                                5.3.3 Blood Tests             

                                5.3.4 Ultrasound             

                                5.3.5 PET             

                                5.3.6 CT Scan     

                                5.3.7 MRI            

                                5.3.8 Human Chorionic Gonadotropin Test          

                                5.3.9 Biopsy       

                                5.3.10 Y-o-Y Growth Analysis, By Diagnosis          

                                5.3.11 Market Attractiveness Analysis, By Diagnosis         

                                5.3.12 Market Share Analysis, By Diagnosis          

                5.4 Treatment                  

                                5.4.1 Introduction           

                                5.4.2 Chemotherapy     

                                5.4.3 Radiation Therapy

                                5.4.4 Hormonal Therapy              

                                5.4.5 Surgery    

                                5.4.6 Immunotherapy   

                                5.4.7 Targeted Therapy

                                5.4.8 Y-o-Y Growth Analysis, By Treatment          

                                5.4.9 Market Attractiveness Analysis, By Treatment         

                                5.4.10 Market Share Analysis, By Treatment       

6. Geographical Analysis                                              

                6.1 Introduction                              

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By Stage of Cancer

                                                6.1.3.3 By Type

                                                6.1.3.4 By Diagnosis

                                                6.1.3.5 By Treatment

                                6.1.4 Market Attractiveness Analysis      

                                                6.1.4.1 By Geographical Area

                                                6.1.3.2 By Stage of Cancer

                                                6.1.3.3 By Type

                                                6.1.3.4 By Diagnosis

                                                6.1.3.5 By Treatment

                                6.1.5 Market Share Analysis        

                                                6.1.5.1 By Geographical Area

                                                6.1.3.2 By Stage of Cancer

                                                6.1.3.3 By Type

                                                6.1.3.4 By Diagnosis

                                                6.1.3.5 By Treatment

                6.2 United States                            

                6.3 Canada                         

7.Strategic Analysis                                        

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental      

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services

                                7.2.5 Competitive Rivalry within the Industry      

8.Market Leaders' Analysis                                          

                8.1 Aetera Zenteris Inc.                

                                8.1.1 Overview

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Eli Lilly and Company                             

                8.3 Roche                           

                8.4 Amgen                         

                8.5 Janssen Pharmaceuticals, Inc.                             

                8.6 Bristol Myers Squibb Company                          

                8.7 Novogen, Inc.                            

                8.8 GlaxoSmithKline                      

                8.9 Boehringer Ingelheim                            

                8.10 AstraZeneca                            

                8.11 Genentech Inc.                       

9.Competitive Landscape                                            

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                        

                9.3 Agreements, collaborations and Joint Ventures                          

                9.4 New Product Launches                          

10.Market Outlook and Investment Opportunities                                           

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  1. North America Ovarian Cancer Market, By Stage Of Cancer, From 2022 - 2027 (USD Billion)
  2. North America Stage I Market, By Region, From 2022 - 2027 (USD Billion)
  3. North America Stage II Market, By Region, From 2022 - 2027 (USD Billion)
  4. North America Stage III Market, By Region, From 2022 - 2027 (USD Billion)
  5. North America Stage IV Market, By Region, From 2022 - 2027 (USD Billion)
  6. North America Ovarian Cancer Market, By Cancer Type, From 2022 - 2027 (USD Billion)
  7. North America Primary Peritoneal Carcinoma Market, By Region, From 2022 - 2027 (USD Billion)
  8. North America Ovarian Stromal Tumors Market, By Region, From 2022 - 2027 (USD Billion)
  9. North America Ovarian Germ Cell Tumors Market, By Region, From 2022 - 2027 (USD Billion)
  10. North America Epithelial Ovarian Tumors Market, By Region, From 2022 - 2027 (USD Billion)
  11. North America Ovarian Cancer Market, By Diagnosis, From 2022 - 2027 (USD Billion)
  12. North America Physical Examination Market, By Region, From 2022 - 2027 (USD Billion)
  13. North America Blood Tests Market, By Region, From 2022 - 2027 (USD Billion)
  14. North America Ultrasound Market, By Region, From 2022 - 2027 (USD Billion)
  15. North America PET Market, By Region, From 2022 - 2027 (USD Billion)
  16. North America CT Scan Market, By Region, From 2022 - 2027 (USD Billion)
  17. North America MRI Market, By Region, From 2022 - 2027 (USD Billion)
  18. North America Human Chorionic Gonadotropin Test Market, By Region, From 2022 - 2027 (USD Billion)
  19. North America Biopsy Market, By Region, From 2022 - 2027 (USD Billion)
  20. North America Ovarian Cancer Market, By Type Of Treatment, From 2022 - 2027 (USD Billion)
  21. North America Chemotherapy Market, By Region, From 2022 - 2027 (USD Billion)
  22. North America Radiation Therapy Market, By Region, From 2022 - 2027 (USD Billion)
  23. North America Hormonal Therapy Market, By Region, From 2022 - 2027 (USD Billion)
  24. North America Surgery Market, By Region, From 2022 - 2027 (USD Billion)
  25. North America Immunotherapy Market, By Region, From 2022 - 2027 (USD Billion)
  26. North America Targeted Therapy Market, By Region, From 2022 - 2027 (USD Billion)
  27. United States Ovarian Cancer Market, By Stage Of Cancer, From 2022 - 2027 (USD Billion)
  28. United States Ovarian Cancer Market, By Cancer Type, From 2022 - 2027 (USD Billion)
  29. United States Ovarian Cancer Market, By Diagnosis, From 2022 - 2027 (USD Billion)
  30. United States Ovarian Cancer Market, By Type Of Treatment, From 2022 - 2027 (USD Billion)
  31. Canada Ovarian Cancer Market, By Stage Of Cancer, From 2022 - 2027 (USD Billion)
  32. Canada Ovarian Cancer Market, By Cancer Type, From 2022 - 2027 (USD Billion)
  33. Canada Ovarian Cancer Market, By Diagnosis, From 2022 - 2027 (USD Billion)
  34. Canada Ovarian Cancer Market, By Type Of Treatment, From 2022 - 2027 (USD Billion)
  35. North America Blood Glucose Monitoring Market, By Stage I, From 2022 - 2027 (USD Billion)
  36. North America Stage IA Market, By Region, From 2022 - 2027 (USD Billion)
  37. North America Stage IB Market, By Region, From 2022 - 2027 (USD Billion)
  38. North America Stage IC Market, By Region, From 2022 - 2027 (USD Billion)
  39. United States Blood Glucose Monitoring Market, By Stage I, From 2022 - 2027 (USD Billion)
  40. Canada Blood Glucose Monitoring Market, By Stage I, From 2022 - 2027 (USD Billion)
  41. North America Blood Glucose Monitoring Market, By Stage II, From 2022 - 2027 (USD Billion)
  42. North America Stage IIA Market, By Region, From 2022 - 2027 (USD Billion)
  43. North America Stage IIB Market, By Region, From 2022 - 2027 (USD Billion)
  44. North America Stage IIC Market, By Region, From 2022 - 2027 (USD Billion)
  45. United States Blood Glucose Monitoring Market, By Stage II, From 2022 - 2027 (USD Billion)
  46. Canada Blood Glucose Monitoring Market, By Stage II, From 2022 - 2027 (USD Billion)
  47. North America Blood Glucose Monitoring Market, By Stage III, From 2022 - 2027 (USD Billion)
  48. North America Stage IIIA Market, By Region, From 2022 - 2027 (USD Billion)
  49. North America Stage IIIB Market, By Region, From 2022 - 2027 (USD Billion)
  50. North America Stage IIIC Market, By Region, From 2022 - 2027 (USD Billion)
  51. United States Blood Glucose Monitoring Market, By Stage III, From 2022 - 2027 (USD Billion)
  52. Canada Blood Glucose Monitoring Market, By Stage III, From 2022 - 2027 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

PURCHASE OPTIONS

excel
$

3335


pdf excel
$

3680


pdf excel powerbi
$

5520


excel
$

2000

What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • 6 Months of Free Analyst Support.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • 1 Year of Free Analyst Support.
  • PDF, Excel and Power BI Dashboard.
  • Can be accessible by unlimited users.
  • 1 Year of Free Analyst Support.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
customer-support
ASK FOR CUSTOMIZATION

Talk to our analyst and get customised report done according to your research needs

tag
INQUIRE FOR DISCOUNT

Check if you can avail any discount. Submit your details and our team will get back to you.

cloud-download
DOWNLOAD FREE SAMPLE

Request to avail a free sample report that reflects this market and its growth.

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 3335

Didn’t find what you’re looking for?
TALK TO OUR TEAM

Find it too expensive?
NO WORRIES!

Click for Request Sample